SG Americas Securities LLC Purchases New Position in Harvard Bioscience, Inc. (NASDAQ:HBIO)

SG Americas Securities LLC acquired a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 13,409 shares of the medical instruments supplier’s stock, valued at approximately $36,000.

Several other large investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Harvard Bioscience in the 2nd quarter worth about $31,000. Cubist Systematic Strategies LLC purchased a new stake in Harvard Bioscience in the second quarter worth about $40,000. Price T Rowe Associates Inc. MD bought a new position in shares of Harvard Bioscience during the first quarter valued at approximately $54,000. Hillsdale Investment Management Inc. purchased a new position in shares of Harvard Bioscience during the first quarter valued at approximately $112,000. Finally, Gabelli Funds LLC bought a new stake in shares of Harvard Bioscience in the 2nd quarter worth approximately $128,000. 80.87% of the stock is owned by institutional investors.

Harvard Bioscience Stock Up 1.2 %

HBIO stock opened at $2.45 on Wednesday. The business has a 50 day moving average of $2.66 and a 200 day moving average of $3.02. The firm has a market cap of $106.40 million, a PE ratio of -12.25 and a beta of 1.29. Harvard Bioscience, Inc. has a twelve month low of $2.30 and a twelve month high of $5.56. The company has a quick ratio of 0.94, a current ratio of 2.05 and a debt-to-equity ratio of 0.48.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.06). The firm had revenue of $23.10 million for the quarter, compared to analysts’ expectations of $29.91 million. Harvard Bioscience had a negative net margin of 10.56% and a negative return on equity of 2.70%. On average, research analysts forecast that Harvard Bioscience, Inc. will post 0.11 EPS for the current fiscal year.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.